SCHEMBL1224892

SCHEMBL1224892

Cc1nn(C)cc1C(N)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.50
ATM Q13315 1/20 0.46
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
NAMPT P43490 1/20 0.45
RAB9A P51151 4/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
ALPL P05186 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.42
NPC1 O15118 3/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
PROKR1 Q8TCW9 1/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
NNMT P40261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29002489 0.81 ADORA2A (0.42) GAAATMALDH1A1SMN1; SMN2NAMPT
SCHEMBL298523 0.81 GAA (0.51) GAAATMALDH1A1SMN1; SMN2NAMPT
SCHEMBL1639886 0.81 GAA (0.51) GAAATMALDH1A1SMN1; SMN2NAMPT
SCHEMBL22987577 0.80 GAA (0.59) GAAATMALDH1A1SMN1; SMN2NAMPT
SCHEMBL23366905 0.80 GAA (0.47) GAAATMALDH1A1SMN1; SMN2NAMPT
SCHEMBL22723715 0.80 GAA (0.44) GAAATMALDH1A1SMN1; SMN2NAMPT
SCHEMBL1833232 0.79 ADORA2A (0.49) GAAADORA2AADORA1
Hydrochloric Acid SCHEMBL10666393 0.79 GAA (0.50) GAAATMALDH1A1SMN1; SMN2NAMPT
SCHEMBL174293 0.79 ADORA2A (0.45) GAAALDH1A1ADORA2AADORA1PROKR1
SCHEMBL976056 0.79 GAA (0.50) GAAATMALDH1A1SMN1; SMN2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 US claimed
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2023-07-06 US claimed
US-11597723-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) 2023-03-07 US claimed
CN-110461854-A Process for preparing chiral 2, 3-dihydrothiazolo [3,2-A ] pyrimidin-4-ium compounds BASF SE 2019-11-15 CN claimed
CN-108117520-A A kind of 1,3- dimethyl -1H- pyrazoles -4- amide derivatives and preparation method and application 浙江工业大学 2018-06-05 CN claimed
CN-105072915-B Synergistic composition comprising bacillus subtilis strain and biological pesticide 巴斯夫公司 2018-05-01 CN claimed
CN-104507316-B Compositions comprising biological control agents and fungicides 拜尔农作物科学股份公司 2018-03-06 CN claimed
CN-105555783-B Include the autotaxin inhibitors of heteroaromatic rings benzyl amide ring core 诺华股份有限公司 2017-12-01 CN claimed
CN-107033084-A A kind of acyl urea compound for containing 1,3 dimethyl 1H pyrrazole structures and its preparation method and application 浙江工业大学 2017-08-11 CN claimed
CN-106962403-A Include biocontrol agent and insecticide composition 拜耳作物科学股份公司 2017-07-21 CN claimed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US claimed
EP-2536731-A1 SUBSTITUTED SPIROINDOLINONES F. Hoffmann-La Roche AG (CH) 2012-12-26 EP claimed
US-8288431-B2 Substituted spiroindolinones HOFFMANN-LA ROCHE INC. (US) 2012-10-16 US claimed
EP-2051983-A1 NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER 4SC AG (DE) 2009-04-29 EP claimed
WO-2008020024-A1 NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER 4SC AG (DE) 2008-02-21 WO claimed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 US claimed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US claimed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP claimed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US claimed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 GAA 264/4885ATM 1223/4885ALDH1A1 1389/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A GAA 352/4885ATM 1805/4885ALDH1A1 862/4885
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC5, ABCC1 GAA 952/4885ATM 1636/4885ALDH1A1 1738/4885
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC1 GAA 952/4885ATM 1636/4885ALDH1A1 1738/4885
US-11597723-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC3 GAA 970/4885ATM 1646/4885ALDH1A1 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.